WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF).

WuXi Biologics completed all of TY014’s CMC studies for Investigational New Drug (IND)
application in record 7 months through its single-source integrated biologics technology
platform. The seamless partnership between Tychan and WuXi Biologics accelerates the
timely delivery of safe and effective therapeutics that are critical for preparedness against
pandemics caused by emerging infectious agents.

“Our successful trials pave the way for a potential first-in-class treatment for Yellow Fever.
This rapid development following the similar achievement for Zika affirms the exciting
collaboration between Tychan and WuXi Biologics to enable a new paradigm to expedite
biologics development initially to address emerging infectious disease outbreaks and
eventually to potentially expand to other therapeutics,” said Teo Ming Kian, Chairman of the
Board, Tychan.

“Congratulations to Tychan on reaching another great milestone with the world’s first
Yellow Fever antibody candidate. We are proud to empower Tychan to expedite the timeline
of high-quality biologics from DNA to clinical trials. Leveraging our strong expertise and
capabilities to accelerate the development and manufacturing of innovative biologics, WuXi
Biologics will continue empowering global partners and allowing them to provide more life-
saving treatments to meet emerging health challenges,” said Dr. Chris Chen, CEO of WuXi
Biologics.